Подписаться
Volker Lauschke
Volker Lauschke
Full Professor, Karolinska Institutet; Deputy Head, IKP
Подтвержден адрес электронной почты в домене ki.se - Главная страница
Название
Процитировано
Процитировано
Год
Characterization of primary human hepatocyte spheroids as a model system for drug-induced liver injury, liver function and disease
CC Bell, DFG Hendriks, SML Moro, E Ellis, J Walsh, A Renblom, ...
Scientific reports 6 (1), 25187, 2016
7222016
Worldwide distribution of cytochrome P450 alleles: a meta‐analysis of population‐scale sequencing projects
Y Zhou, M Ingelman‐Sundberg, VM Lauschke
Clinical Pharmacology & Therapeutics 102 (4), 688-700, 2017
6142017
A 12-gene pharmacogenetic panel to prevent adverse drug reactions: an open-label, multicentre, controlled, cluster-randomised crossover implementation study
JJ Swen, CH van der Wouden, LEN Manson, H Abdullah-Koolmees, ...
The Lancet 401 (10374), 347-356, 2023
3262023
Comparison of hepatic 2D sandwich cultures and 3D spheroids for long-term toxicity applications: a multicenter study
CC Bell, ACA Dankers, VM Lauschke, R Sison-Young, R Jenkins, ...
Toxicological Sciences 162 (2), 655-666, 2018
3132018
Mechanism of baricitinib supports artificial intelligence‐predicted testing in COVID‐19 patients
J Stebbing, V Krishnan, S de Bono, S Ottaviani, G Casalini, ...
EMBO molecular medicine 12 (8), e12697, 2020
3022020
Novel 3D culture systems for studies of human liver function and assessments of the hepatotoxicity of drugs and drug candidates
VM Lauschke, DFG Hendriks, CC Bell, TB Andersson, ...
Chemical research in toxicology 29 (12), 1936-1955, 2016
2572016
Rare genetic variants in cellular transporters, metabolic enzymes, and nuclear receptors can be important determinants of interindividual differences in drug response
M Kozyra, M Ingelman-Sundberg, VM Lauschke
Genetics in Medicine 19 (1), 20-29, 2017
2362017
Integrating rare genetic variants into pharmacogenetic drug response predictions
M Ingelman-Sundberg, S Mkrtchian, Y Zhou, VM Lauschke
Human genomics 12, 1-12, 2018
2232018
Scaling of embryonic patterning based on phase-gradient encoding
VM Lauschke, CD Tsiairis, P François, A Aulehla
Nature 493 (7430), 101-105, 2013
2132013
Pharmacogenetic allele nomenclature: International workgroup recommendations for test result reporting
LV Kalman, JAG Agúndez, ML Appell, JL Black, GC Bell, S Boukouvala, ...
Clinical Pharmacology & Therapeutics 99 (2), 172-185, 2016
2122016
JAK inhibition reduces SARS-CoV-2 liver infectivity and modulates inflammatory responses to reduce morbidity and mortality
J Stebbing, G Sánchez Nievas, M Falcone, S Youhanna, P Richardson, ...
Science advances 7 (1), eabe4724, 2021
2072021
Modulation of phase shift between Wnt and Notch signaling oscillations controls mesoderm segmentation
KF Sonnen, VM Lauschke, J Uraji, HJ Falk, Y Petersen, MC Funk, ...
Cell 172 (5), 1079-1090. e12, 2018
1892018
Transcriptional, functional, and mechanistic comparisons of stem cell–derived hepatocytes, HepaRG cells, and three-dimensional human hepatocyte spheroids as predictive in vitro …
CC Bell, VM Lauschke, SU Vorrink, H Palmgren, R Duffin, TB Andersson, ...
Drug Metabolism and Disposition 45 (4), 419-429, 2017
1892017
Prediction of drug-induced hepatotoxicity using long-term stable primary hepatic 3D spheroid cultures in chemically defined conditions
SU Vorrink, Y Zhou, M Ingelman-Sundberg, VM Lauschke
Toxicological Sciences 163 (2), 655-665, 2018
1852018
Human hepatic 3D spheroids as a model for steatosis and insulin resistance
M Kozyra, I Johansson, Å Nordling, S Ullah, VM Lauschke, ...
Scientific reports 8 (1), 14297, 2018
1742018
Endogenous and xenobiotic metabolic stability of primary human hepatocytes in long-term 3D spheroid cultures revealed by a combination of targeted and untargeted metabolomics
SU Vorrink, S Ullah, S Schmidt, J Nandania, V Velagapudi, O Beck, ...
The FASEB Journal 31 (6), 2696, 2017
1692017
Pharmacogenomic biomarkers for improved drug therapy—recent progress and future developments
VM Lauschke, L Milani, M Ingelman-Sundberg
The AAPS journal 20, 1-16, 2018
1512018
3D primary hepatocyte culture systems for analyses of liver diseases, drug metabolism, and toxicity: emerging culture paradigms and applications
VM Lauschke, RZ Shafagh, DFG Hendriks, M Ingelman‐Sundberg
Biotechnology journal 14 (7), 1800347, 2019
1462019
Genetic variation in the human cytochrome P450 supergene family
K Fujikura, M Ingelman-Sundberg, VM Lauschke
Pharmacogenetics and genomics 25 (12), 584-594, 2015
1452015
An optimized prediction framework to assess the functional impact of pharmacogenetic variants
Y Zhou, S Mkrtchian, M Kumondai, M Hiratsuka, VM Lauschke
The pharmacogenomics journal 19 (2), 115-126, 2019
1322019
В данный момент система не может выполнить эту операцию. Повторите попытку позднее.
Статьи 1–20